Compare · BMRA vs NEOG
BMRA vs NEOG
Side-by-side comparison of Biomerica Inc. (BMRA) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.07B, about 306.5x BMRA ($6.8M).
- Over the past year, BMRA is down 42.3% and NEOG is up 65.6% - NEOG leads by 107.9 points.
- NEOG has been more active in the news (7 items in the past 4 weeks vs 5 for BMRA).
- NEOG has more recent analyst coverage (5 ratings vs 0 for BMRA).
- Company
- Biomerica Inc.
- Neogen Corporation
- Price
- $2.18-0.91%
- $9.52+1.38%
- Market cap
- $6.8M
- $2.07B
- 1M return
- -0.91%
- +1.28%
- 1Y return
- -42.33%
- +65.57%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 5
- 7
- Recent ratings
- 0
- 5
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest BMRA
- Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
- Biomerica Reports Third Quarter Fiscal 2026 Financial Results
- SEC Form 10-Q filed by Biomerica Inc.
- Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
- Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
- SEC Form S-8 filed by Biomerica Inc.
- Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
- Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution
Latest NEOG
- Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
- Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Stacey Jennifer Evans
- SEC Form 10-Q filed by Neogen Corporation
- Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neogen Reports Third Quarter Fiscal Year 2026 Financial Results
- Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
- Neogen Corporation filed SEC Form 8-K: Leadership Update
- Neogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Neogen Corporation